Legend:
CC = Baltimore Convention Center,
H = Hilton Baltimore
* = applied session ! = JSM meeting theme
|
|
|
|
208 * !
|
Mon, 7/31/2017,
2:00 PM -
3:50 PM
|
CC-322
|
|
Substantial Evidence Using Bayesian Statistics in New Drug Approvals — Invited Papers
|
|
Section on Bayesian Statistical Science , Health Policy Statistics Section , Statistics and Public Policy
|
|
Organizer(s): Fanni Natanegara, Eli Lilly and Company
|
|
Chair(s): Fanni Natanegara, Eli Lilly and Company
|
|
2:05 PM
|
A Global Oncology Platform Trial for Personalized Medicine: GBM AGILE
—
Jason Connor, Berry Consultants
|
|
2:20 PM
|
Predictive Evidence Threshold Scaling: Does the Evidence Meet a Confirmatory Standard?
—
Satrajit Roychoudhury, Pfizer Inc ; Beat Neuenschwander, Novartis Pharma AG ; Michael Branson, Novartis Pharma AG
|
|
2:35 PM
|
Shedding a Bayesian Light on the Evidence-Based Medicine
—
J. Jack Lee, UT MD Anderson Cancer Ctr.
|
|
2:50 PM
|
Re-Analyzing Clinical Trials Through the Bayesian Lens
—
Margaret Gamalo-Siebers, Eli Lilly ; Karen Price, Eli Lilly ; Stephen J Ruberg, Eli Lilly and Co
|
|
3:05 PM
|
Discussant: Stephen J Ruberg, Eli Lilly and Co
|
|
3:20 PM
|
Discussant: John Scott, FDA
|
|
3:35 PM
|
Floor Discussion
|
